TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has announced two significant developments: the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the execution of a sponsored research agreement with Michigan State University. These moves are aimed at advancing the company's RNA-based therapeutic pipeline, particularly its lead candidate TTX-MC138, which targets metastatic tumors overexpressing microRNA-10b.
The appointment of Dr. Moore, a renowned expert in molecular imaging and nanomedicine, is expected to provide strategic guidance on research and development efforts focused on treating advanced cancers. Dr. Moore's experience includes serving as a professor at Michigan State University and previously at Harvard Medical School, where she directed the Molecular Imaging Laboratory. Her leadership will be crucial as TransCode seeks to navigate the complexities of developing RNA-based therapies for high-risk and advanced cancers.
The sponsored research agreement with Michigan State University will support further development of TTX-MC138, including evaluation in combination with other therapies. This collaboration leverages the university's research capabilities to potentially enhance the efficacy of TransCode's lead candidate. TTX-MC138 is designed to target metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The company believes that this approach could address a significant unmet need in oncology, as metastasis is responsible for the majority of cancer-related deaths.
TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA-based treatments. Beyond TTX-MC138, the company has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. These developments come at a critical time when the field of RNA therapeutics is gaining momentum, with recent successes in mRNA vaccines highlighting the potential of RNA-based approaches.
The announcement underscores TransCode's commitment to advancing its pipeline through strategic partnerships and expert guidance. Investors and stakeholders will be watching closely as the company moves forward with its clinical programs. For more details, the full press release is available at https://ibn.fm/NA2NH. Latest news and updates relating to RNAZ can be found at https://ibn.fm/RNAZ.
